2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.0 - Release 2022.1

This page is part of the 2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide (v2022.1.0: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

2022 CDC Clinical Practice Guideline - Terminology

Contents:

Note that the terminologies included in this implementation guide contain point-in-time expansions, as of the date of publication in the ValueSet resources. Before use in a production environment, ensure you have the latest expansions based on the definitions for each value set.

The following terminology artifacts have been defined for the 2022 CDC Clinical Practice Guideline implementation guide:

CodeSystems

  • CodeSystem - CDC 2022 Opioid Indicator
  • CDC Opioid Override Reasons

    • ValueSets

  • All urine drug screening tests
  • Amphetamine-class drugs and metabolite urine tests
  • Amphetamine class medications
  • Barbiturate Medications
  • Barbiturate urine drug screening tests
  • Benzodiazepine medications
  • Benzodiazepine urine drug screening tests
  • Buprenorphine and Methadone medications
  • Buprenorphine Medications
  • Buprenorphine urine drug screening tests
  • Cannabinoid class urine drug screening
  • CDC malignant cancer conditions
  • CNS depressant medications
  • Cocaine urine drug screening tests
  • Sleep disordered breathing
  • Conditions documenting substance misuse
  • Conditions likely terminal for opioid prescribing
  • Extended release opioid with ambulatory misuse potential
  • Fentanyl-type medications
  • Fentanyl-type urine drug screening tests
  • General opiate urine drug screening tests
  • Heroin urine drug screening tests
  • Hospice Finding
  • Hospice Procedure
  • Limited life expectancy conditions
  • Methadone medications
  • Methadone urine drug screening tests
  • Naloxone medications
  • Non-opioid drug urine screening
  • Non-synthetic opioid medications
  • Oncology specialty designations (NUCC)
  • Opiate specific urine drug screening tests
  • Opioid analgesics with ambulatory misuse potential
  • Opioid counseling procedure
  • Opioid misuse assessment procedure
  • Opioid misuse disorders
  • Opioid treatment assessment procedure
  • Opioid drug urine screening
  • Oxycodone Medications
  • Oxycodone urine drug screening tests
  • Pain management procedure
  • Pain treatment plan
  • PDMP data reviewed finding
  • PDMP review procedure
  • Phencyclidine urine drug screening tests
  • Sickle-cell diseases
  • Substance misuse behavioral counseling
  • Synthetic opioid medications
  • Synthetic opioid urine drug screening tests
  • Therapies indicating end of life care
  • Condition Clinical Status Active
  • Encounter Diagnosis Condition Category
  • Problem List Condition Category
  • US Core Health Concern Condition Category
  • Hospice Disposition
  • ValueSet - Medication Request Category Community
  • ValueSet - Medication Request Status Active
  • Observation Category Laboratory
  • Observation Category Procedure
  • Office Visit
  • Xylazine drug urine screening tests